QUEBEC CITY, June 2 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"),
today announced that Mr. Andy Sheldon, President and CEO, will participate in
a panel discussion entitled "Addressing the limited global capacity in
producing pandemic and seasonal flu vaccines" at the World Vaccine Congress
Asia 2008. The conference will be held at the Grand Hyatt Singapore,
Singapore, from June 2-5, 2008.
During the session, Mr. Sheldon and other leading vaccine experts will
describe what are the technical manufacturing challenges and strategies to
increase vaccine production capacity, as well as discuss the continuous
progress to improve vaccine production technology and production of vaccines
for broader protection.
World Vaccine Congress Asia 2008 is a meeting where vaccine buyers and
sellers, health authorities, financing institutions, regulators, vaccine
producers and manufacturers, technology providers and other stakeholders come
together to discuss industry trend, market and partnership opportunities, new
vaccines and new technology innovations across Asia.
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.
Forward Looking Statements
This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release
For further information:
For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations: The Equicom Group Inc., Arianna
Vanin, P (514) 844-4680, email@example.com